• LAST PRICE
    0.3950
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.3533/ 50
  • Ask / Lots
    0.3831/ 1
  • Open / Previous Close
    --- / 0.3950
  • Day Range
    ---
  • 52 Week Range
    Low 0.3011
    High 2.9300
  • Volume
    801
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.3757
TimeVolumeFGEN
09:32 ET112960.38
09:34 ET5210.3792
09:36 ET8950.3732
09:39 ET41100.3736
09:41 ET6000.379
09:45 ET10000.3792
09:56 ET94000.37685
09:57 ET4000.37685
09:59 ET2900.3768
10:03 ET50000.378199
10:06 ET2500.37715
10:08 ET12000.377574
10:10 ET66500.3758
10:12 ET2960.37605
10:14 ET28520.3744
10:15 ET28200.37445
10:17 ET13100.37445
10:19 ET21090.3744
10:24 ET86000.3709
10:28 ET2000.3743
10:30 ET3000.3729
10:32 ET14500.3726
10:33 ET1000.3711
10:39 ET26240.3706
10:44 ET1210.3713
10:51 ET3200.3739
10:53 ET1000.374
11:00 ET1000.371825
11:08 ET1000.372551
11:18 ET1000.3725
11:20 ET3000.3725
11:22 ET20000.3725
11:24 ET2000.3725
11:26 ET1000.3725
11:27 ET4000.37355
11:29 ET2000.37355
11:31 ET22000.3712
11:33 ET1000.3734
11:36 ET1000.3734
11:38 ET2000.3734
11:40 ET4400.371854
11:42 ET1000.3732
11:44 ET61070.37565
11:45 ET2530.3757
11:47 ET10000.3767
11:51 ET16660.3777
11:56 ET27000.377681
12:00 ET31750.3758
12:03 ET393050.3784
12:05 ET14580.3802
12:07 ET4000.3815
12:09 ET1000.3807
12:12 ET4990.3807
12:14 ET19270.3799
12:16 ET9000.3809
12:18 ET2000.3814
12:20 ET3600.381
12:23 ET8000.38
12:25 ET1000.3805
12:27 ET12000.3805
12:30 ET1000.3805
12:34 ET3440.3808
12:36 ET56000.381
12:38 ET3000.38155
12:39 ET3000.38155
12:41 ET59000.3812
12:43 ET76170.3832
12:45 ET5900.38415
12:48 ET1000.385
12:50 ET1000.38415
12:52 ET124430.3833
12:54 ET10000.3828
12:56 ET33000.3828
12:59 ET7880.3812
01:01 ET253910.3794
01:06 ET4390.3806
01:08 ET15870.3807
01:10 ET10000.3806
01:12 ET6510.3807
01:14 ET5250.3807
01:15 ET1000.38005
01:17 ET102770.3795
01:24 ET38690.3816
01:26 ET2810.3835
01:30 ET20140.3834
01:33 ET4700.38096
01:39 ET4340.38
01:46 ET31920.3815
01:48 ET47000.3815
01:50 ET17000.3815
01:51 ET2000.3807
01:53 ET113640.382201
01:57 ET29040.3814
02:00 ET1000.3827
02:02 ET6000.3824
02:04 ET35000.3834
02:06 ET4850.3845
02:20 ET10000.3832
02:22 ET2500.383343
02:24 ET6000.3838
02:31 ET13330.3843
02:33 ET142950.3844
02:36 ET1000.383699
02:38 ET1270.3844
02:42 ET4930.3843
02:45 ET119980.3844
02:47 ET14970.3844
02:49 ET95680.3846
02:51 ET30930.385
02:56 ET6280.3849
03:02 ET1000.38495
03:03 ET6000.3849
03:05 ET1000.3849
03:09 ET1000.385
03:16 ET14100.38495
03:18 ET2000.385
03:21 ET1250.385
03:25 ET5000.3849
03:27 ET10000.385
03:30 ET21910.385
03:36 ET176020.3849
03:38 ET482570.393
03:39 ET40350.393
03:41 ET12000.3901
03:45 ET307940.388547
03:50 ET45000.3882
03:52 ET2000.39
03:54 ET1120.3885
03:56 ET3000.39
03:57 ET34980.3902
03:59 ET832440.395
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesFGEN
FibroGen Inc
39.7M
-0.2x
---
United StatesKPTI
Karyopharm Therapeutics Inc
106.5M
-1.0x
---
United StatesAGEN
Agenus Inc
98.6M
-0.4x
---
United StatesMCRB
Seres Therapeutics Inc
143.5M
-0.7x
---
United StatesKMDA
Kamada Ltd
304.7M
17.9x
-22.48%
United StatesSTRO
Sutro Biopharma Inc
304.1M
-2.0x
---
As of 2024-10-18

Company Information

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.

Contact Information

Headquarters
350 BAY STREET, SUITE 100 #6009SAN FRANCISCO, CA, United States 94133
Phone
415-978-1200
Fax
415-978-1902

Executives

Independent Chairman of the Board
James Schoeneck
Chief Executive Officer, Director
Thane Wettig
Chief Financial Officer
Juan Graham
Senior Vice President, Chief Medical Officer
Deyaa Adib
Senior Vice President, China Operations
Christine Chung

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$39.7M
Revenue (TTM)
$173.8M
Shares Outstanding
100.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.70
EPS
$-1.71
Book Value
$-2.07
P/E Ratio
-0.2x
Price/Sales (TTM)
0.2
Price/Cash Flow (TTM)
---
Operating Margin
-91.86%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.